# US 2017/0281680 A1 · Scaffold Delivery of Immune Suppressors and Transplant Material for Control of Transplant Rejection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281680 A1
- Document ID: US20170281680A1
- Status: Published application
- Kind: A1
- Application number: 15/351,017
- Filed: 2016-11-14
- Published: 2017-10-05
- Earliest claimed: 2012-10-31
- Assignees: Northwestern University
- Applicants: Northwestern University
- Inventors: Xunrong Luo; Lonnie Shea; John G. Graham; Kathryn L. Pothoven; Xiaomin Zhang
- Web page: https://patentgrep.com/patent/US20170281680A1

## CPC

- A61K 35/39: Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K35/36)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 40/418: {Antigens related to induction of tolerance to non-self}
- A61L 27/18: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 27/3804: {characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61L 27/58: Materials at least partially resorbable by the body
- A61K 2239/31: characterized by the route of administration
- A61L 2300/64: Animal cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

The present invention provides compositions, devices, and methods for the coordinated delivery of transplant material and immune suppressors for control of transplant rejection. In particular embodiments, immune suppression cells (e.g., regulatory T cells) and transplant material (e.g., cells, tissue, etc.) are provided within a delivery scaffold for transplant into a subject.

## Claims

### Claim 1

A system comprising:
(a) a delivery scaffold;
(b) transplantable material; and
(c) immune suppression cells.

### Claim 2 (depends on 1)

The system of claim 1, wherein the scaffold comprises a polymer matrix.

### Claim 3 (depends on 1)

The system of claim 1, wherein the scaffold is porous.

### Claim 4 (depends on 2)

The system of claim 2, wherein the polymer matrix comprises a biocompatible and biodegradable polymer.

### Claim 5 (depends on 4)

The system of claim 4, wherein the polymer matrix comprises poly(lactide-co-glycolide).

### Claim 7 (depends on 1)

The system of claim 1, wherein the scaffold is fabricated in any shape suitable for implantation into a transplantation site on a subject.

### Claim 8 (depends on 1)

The system of claim 1, wherein the scaffold comprises multiple layers.

### Claim 9 (depends on 1)

The system of claim 1, wherein the transplantable material comprises cells or a tissue.

### Claim 10 (depends on 9)

The system of claim 9, wherein the transplantable material comprises islet cells.

### Claim 11 (depends on 1)

The system of claim 1, wherein the immune suppression cells comprise Treg cells.

### Claim 12

A method for enhancing the incorporation of transplant material into a subject comprising:
(a) providing the transplant material and immune suppression cells on or within a delivery scaffold; and
(b) transplanting the delivery scaffold into a transplantation site on a subject.

### Claim 13 (depends on 12)

The method of claim 12, wherein the scaffold comprises a polymer matrix.

### Claim 14 (depends on 12)

The method of claim 12, wherein the scaffold is porous.

### Claim 15 (depends on 13)

The method of claim 13, wherein the polymer matrix comprises a biocompatible and biodegradable polymer.

### Claim 16 (depends on 13)

The method of claim 13, wherein the polymer matrix comprises poly(lactide-co-glycolide).

### Claim 17 (depends on 12)

The method of claim 12, wherein the transplantable material comprises cells or a tissue.

### Claim 18 (depends on 17)

The method of claim 17, wherein the transplantable material comprises islet cells.

### Claim 19 (depends on 12)

The method of claim 12, wherein the immune suppression cells comprise Treg cells.

### Claim 20 (depends on 18)

The method of claim 18, wherein the islet cells are transplanted in the subject to treat type 1 diabetes.
